세계의 표적 리포솜 약물전달 시장

Global Targeted Liposomes Drug Delivery Market to Reach US$4.5 Billion by 2030

The global market for Targeted Liposomes Drug Delivery estimated at US$2.7 Billion in the year 2024, is expected to reach US$4.5 Billion by 2030, growing at a CAGR of 9.1% over the analysis period 2024-2030. Liposomal Doxorubicin, one of the segments analyzed in the report, is expected to record a 9.8% CAGR and reach US$2.3 Billion by the end of the analysis period. Growth in the Liposomal Paclitaxel segment is estimated at 10.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$709.4 Million While China is Forecast to Grow at 8.8% CAGR

The Targeted Liposomes Drug Delivery market in the U.S. is estimated at US$709.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$723.8 Million by the year 2030 trailing a CAGR of 8.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.4% and 7.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.2% CAGR.

Global "Targeted Liposomes Drug Delivery" Market - Key Trends & Drivers Summarized

How Are Liposomes Unlocking Precision in Drug Delivery?

Targeted liposomes have emerged as one of the most sophisticated tools in precision medicine, revolutionizing how therapeutic compounds are delivered to specific cells or tissues. These nanoscale, lipid-based vesicles encapsulate drugs within aqueous cores or lipid bilayers, enhancing bioavailability, reducing toxicity, and allowing for controlled release. Unlike traditional drug delivery methods, which often disperse active agents systemically and indiscriminately, targeted liposomes use surface modifications-such as ligands, antibodies, peptides, or aptamers-to home in on receptors uniquely expressed on diseased cells, especially in cancer and inflammatory disorders.

This selectivity has turned liposomes into an invaluable platform in oncology, where they deliver chemotherapy agents like doxorubicin or paclitaxel directly to tumor sites, minimizing damage to healthy tissue. The FDA-approved formulations such as Doxil and Onivyde underscore their clinical viability and therapeutic impact. Liposomes also enable co-delivery of multiple drugs, paving the way for synergistic treatments that address drug resistance. Their biodegradability and low immunogenicity make them ideal for chronic and recurrent diseases requiring repeat dosing. This transformative ability to merge pharmacology with targeting precision is pushing targeted liposomes to the forefront of next-generation drug delivery systems.

What Innovations Are Enhancing Liposome Functionality and Targeting Accuracy?

Technological advances are rapidly refining how liposomes are constructed, functionalized, and deployed. The development of PEGylated liposomes-coated with polyethylene glycol-has extended circulation time in the bloodstream by preventing rapid clearance by the immune system. Meanwhile, ligand-conjugated liposomes are being engineered to bind with exquisite specificity to cellular markers overexpressed in diseases such as HER2+ breast cancer, EGFR-driven lung tumors, or CD44-expressing leukemias. This approach enhances intracellular uptake and improves drug retention at the target site.

Encapsulation techniques have also seen significant improvement. Remote loading methods, which exploit pH or ionic gradients, offer higher drug loading efficiency and stability compared to passive techniques. Additionally, stimuli-responsive liposomes-triggered by pH, temperature, enzymes, or external radiation-are enabling spatially and temporally controlled drug release, particularly useful in solid tumors where microenvironmental conditions differ from normal tissue. Microfluidic technologies are now enabling precision manufacturing of liposomes at scale with highly uniform size distributions, crucial for clinical efficacy and reproducibility. These scientific advancements are transforming liposomes into customizable, multifunctional nanocarriers capable of addressing previously intractable pharmacological challenges.

Where Are Targeted Liposomes Making the Greatest Clinical Impact Today?

The greatest clinical impact of targeted liposomes is currently being realized in oncology, infectious disease treatment, and rare genetic disorders. In cancer care, liposomal drug formulations are being used in the treatment of breast, ovarian, pancreatic, and liver cancers, where systemic chemotherapy often leads to dose-limiting toxicities. Liposomes not only shield normal cells but also allow for higher drug concentrations at the tumor site, increasing therapeutic efficacy. In hematological malignancies, liposome-based delivery of RNAi therapeutics is enabling gene silencing strategies that suppress oncogenes directly within diseased cells.

Beyond oncology, liposomes are gaining traction in the treatment of fungal and bacterial infections. Liposomal amphotericin B, for instance, has dramatically improved the safety profile of this potent antifungal drug, making it a mainstay in immunocompromised patients. In gene therapy and mRNA delivery, liposomes are being adapted into lipid nanoparticles (LNPs)-a close cousin-which played a pivotal role in the COVID-19 mRNA vaccines, proving their scalability and translational power. Additionally, rare disease treatments are beginning to adopt liposomal platforms to address lysosomal storage diseases and metabolic disorders, where precise intracellular delivery is critical. Pediatric applications are also expanding, as liposomes offer safer, lower-dose alternatives with improved compliance in young patients. The wide therapeutic applicability of targeted liposomes is making them a cornerstone of personalized, precision-driven pharmacotherapy.

The Growth in the Targeted Liposomes Drug Delivery Market Is Driven by Several Factors…

The growth in the targeted liposomes drug delivery market is driven by several factors rooted in pharmaceutical innovation, rising clinical demand for targeted therapies, and shifting regulatory and patient preferences. Chief among these is the increasing focus on personalized medicine, which requires delivery systems capable of targeting molecular subtypes of diseases with precision. Liposomes, owing to their modifiable structure and low immunogenicity, are ideally suited for such tasks. Technological advances in lipid chemistry, ligand conjugation, and nanoformulation manufacturing are allowing for more efficient drug encapsulation, controlled release, and receptor-specific targeting.

From an end-use perspective, oncology remains the largest driver, with hospitals and specialty clinics favoring liposomal therapies to manage chemotherapy side effects and improve treatment tolerability. Consumer behavior is also evolving, with patients and physicians showing greater acceptance of nanomedicine-based therapies, especially those that offer fewer systemic side effects. The success of LNP-based COVID-19 vaccines has validated the use of lipid-based carriers, increasing investor confidence and fast-tracking R&D in liposome platforms for various chronic and infectious diseases. Moreover, regulatory bodies are providing expedited pathways and orphan drug designations to liposome-based formulations, especially for rare diseases and unmet medical needs. Finally, strategic partnerships between pharmaceutical companies, biotech start-ups, and research institutions are accelerating the development of liposome-enabled drugs, making the market both highly competitive and innovation-driven.

SCOPE OF STUDY:

The report analyzes the Targeted Liposomes Drug Delivery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, Other Types); Application (Fungal Infection Therapy, Cancer Therapy, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

• Acuitas Therapeutics
• Arrowhead Pharmaceuticals
• Baxter International
• Camurus AB
• Catalent, Inc.
• Evonik Industries AG
• Fareva
• Genmab
• Gilead Sciences, Inc.
• Ipsen Biopharmaceuticals, Inc.
• Johnson & Johnson
• Lonza Group
• Merck KGaA
• Novartis AG
• Pacira BioSciences, Inc.
• Pfizer Inc.
• Recipharm AB
• Takeda Pharmaceutical Company Limited
• Vetter Pharma
• Xiamen Amoytop Biotech Co., Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Targeted Liposomes Drug Delivery - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Prevalence of Cancer and Chronic Diseases Propels Demand for Targeted Delivery Systems
  • Advancements in Liposome Formulation Technology Spur Innovation
  • Growing Interest in Precision Medicine Strengthens Market Opportunities
  • Regulatory Support for Nanomedicine Development Accelerates Product Approvals
  • Enhanced Bioavailability and Reduced Toxicity Drive Liposomal Adoption
  • Expansion of Liposomal Vaccines Market Boosts Industry Penetration
  • Sustained Growth in Injectable Drug Market Spurs Liposome Usage
  • Nanocarrier Platform Licensing Deals Open New Revenue Streams
  • Growing Role of AI in Lipid Nanoparticle Design Enhances Targeting Efficiency
  • Favorable Intellectual Property Landscape Supports Competitive Differentiation
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Targeted Liposomes Drug Delivery Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Targeted Liposomes Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Targeted Liposomes Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Liposomal Doxorubicin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Liposomal Doxorubicin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Liposomal Doxorubicin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Liposomal Paclitaxel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Liposomal Paclitaxel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Liposomal Paclitaxel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Liposomal Amphotericin B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Liposomal Amphotericin B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Liposomal Amphotericin B by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Fungal Infection Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Fungal Infection Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Fungal Infection Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Cancer Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Cancer Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Cancer Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Targeted Liposomes Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: USA 15-Year Perspective for Targeted Liposomes Drug Delivery by Type - Percentage Breakdown of Value Sales for Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types for the Years 2015, 2025 & 2030
  • TABLE 29: USA Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: USA 15-Year Perspective for Targeted Liposomes Drug Delivery by Application - Percentage Breakdown of Value Sales for Fungal Infection Therapy, Cancer Therapy and Other Applications for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: Canada 15-Year Perspective for Targeted Liposomes Drug Delivery by Type - Percentage Breakdown of Value Sales for Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types for the Years 2015, 2025 & 2030
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: Canada 15-Year Perspective for Targeted Liposomes Drug Delivery by Application - Percentage Breakdown of Value Sales for Fungal Infection Therapy, Cancer Therapy and Other Applications for the Years 2015, 2025 & 2030
• JAPAN
  • Targeted Liposomes Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: Japan 15-Year Perspective for Targeted Liposomes Drug Delivery by Type - Percentage Breakdown of Value Sales for Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types for the Years 2015, 2025 & 2030
  • TABLE 41: Japan Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Japan 15-Year Perspective for Targeted Liposomes Drug Delivery by Application - Percentage Breakdown of Value Sales for Fungal Infection Therapy, Cancer Therapy and Other Applications for the Years 2015, 2025 & 2030
• CHINA
  • Targeted Liposomes Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 44: China Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: China Historic Review for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: China 15-Year Perspective for Targeted Liposomes Drug Delivery by Type - Percentage Breakdown of Value Sales for Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types for the Years 2015, 2025 & 2030
  • TABLE 47: China Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: China Historic Review for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: China 15-Year Perspective for Targeted Liposomes Drug Delivery by Application - Percentage Breakdown of Value Sales for Fungal Infection Therapy, Cancer Therapy and Other Applications for the Years 2015, 2025 & 2030
• EUROPE
  • Targeted Liposomes Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Targeted Liposomes Drug Delivery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Europe 15-Year Perspective for Targeted Liposomes Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Europe 15-Year Perspective for Targeted Liposomes Drug Delivery by Type - Percentage Breakdown of Value Sales for Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types for the Years 2015, 2025 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Europe 15-Year Perspective for Targeted Liposomes Drug Delivery by Application - Percentage Breakdown of Value Sales for Fungal Infection Therapy, Cancer Therapy and Other Applications for the Years 2015, 2025 & 2030
• FRANCE
  • Targeted Liposomes Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 59: France Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: France Historic Review for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: France 15-Year Perspective for Targeted Liposomes Drug Delivery by Type - Percentage Breakdown of Value Sales for Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types for the Years 2015, 2025 & 2030
  • TABLE 62: France Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: France Historic Review for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: France 15-Year Perspective for Targeted Liposomes Drug Delivery by Application - Percentage Breakdown of Value Sales for Fungal Infection Therapy, Cancer Therapy and Other Applications for the Years 2015, 2025 & 2030
• GERMANY
  • Targeted Liposomes Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 65: Germany Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Germany 15-Year Perspective for Targeted Liposomes Drug Delivery by Type - Percentage Breakdown of Value Sales for Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types for the Years 2015, 2025 & 2030
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Germany Historic Review for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Germany 15-Year Perspective for Targeted Liposomes Drug Delivery by Application - Percentage Breakdown of Value Sales for Fungal Infection Therapy, Cancer Therapy and Other Applications for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 71: Italy Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Italy 15-Year Perspective for Targeted Liposomes Drug Delivery by Type - Percentage Breakdown of Value Sales for Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types for the Years 2015, 2025 & 2030
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Italy Historic Review for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Italy 15-Year Perspective for Targeted Liposomes Drug Delivery by Application - Percentage Breakdown of Value Sales for Fungal Infection Therapy, Cancer Therapy and Other Applications for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Targeted Liposomes Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 77: UK Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: UK 15-Year Perspective for Targeted Liposomes Drug Delivery by Type - Percentage Breakdown of Value Sales for Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types for the Years 2015, 2025 & 2030
  • TABLE 80: UK Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: UK Historic Review for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: UK 15-Year Perspective for Targeted Liposomes Drug Delivery by Application - Percentage Breakdown of Value Sales for Fungal Infection Therapy, Cancer Therapy and Other Applications for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Rest of Europe Historic Review for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Rest of Europe 15-Year Perspective for Targeted Liposomes Drug Delivery by Type - Percentage Breakdown of Value Sales for Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types for the Years 2015, 2025 & 2030
  • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Rest of Europe Historic Review for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Rest of Europe 15-Year Perspective for Targeted Liposomes Drug Delivery by Application - Percentage Breakdown of Value Sales for Fungal Infection Therapy, Cancer Therapy and Other Applications for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Targeted Liposomes Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Asia-Pacific Historic Review for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Asia-Pacific 15-Year Perspective for Targeted Liposomes Drug Delivery by Type - Percentage Breakdown of Value Sales for Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types for the Years 2015, 2025 & 2030
  • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Asia-Pacific Historic Review for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Asia-Pacific 15-Year Perspective for Targeted Liposomes Drug Delivery by Application - Percentage Breakdown of Value Sales for Fungal Infection Therapy, Cancer Therapy and Other Applications for the Years 2015, 2025 & 2030
• REST OF WORLD
  • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Rest of World Historic Review for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Rest of World 15-Year Perspective for Targeted Liposomes Drug Delivery by Type - Percentage Breakdown of Value Sales for Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types for the Years 2015, 2025 & 2030
  • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Rest of World Historic Review for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Rest of World 15-Year Perspective for Targeted Liposomes Drug Delivery by Application - Percentage Breakdown of Value Sales for Fungal Infection Therapy, Cancer Therapy and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION